natgillin/translations-raw huggingface dataset:
Avian infectious laryngotracheitis and Marek's disease vaccine (live recombinant) 
cepivo proti aviarnemu infekcijskemu laringotraheitisu in Marekovi bolezni (živo, rekombinantno)
Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. 
Piščanci se okužijo v zgodnjem življenjskem obdobju z vdihavanjem prhljaja (delčkov kože), ki vsebuje virus in je lahko kužen še več mesecev po tem, ko odpade s telesa.
Innovax-ILT is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription. 
Zdravilo Innovax-ILT je na voljo v obliki suspenzije in vehikla za pripravo suspenzije za injiciranje in se izdaja le na recept.
What is Innovax-ILT and what is it used for? 
Kaj je zdravilo Innovax-ILT in za kaj se uporablja?
The turkey herpesvirus strain HVT/ILT-138 has been modified so that it will produce the glycoproteins gD and gI which form part of the outer coat of the ILT virus. 
Sev puranjega herpes virusa HVT/ILT-138 je bil spremenjen tako, da tvori glikoproteina gD in gI, ki sestavljata zunanjo ovojnico virusa ILT.
What benefits of Innovax-ILT have been shown in studies? 
Kakšne koristi je zdravilo Innovax-ILT izkazalo v študijah?
Innovax-ILT is a vaccine containing turkey herpesvirus serotype 3, a type of herpesvirus which is closely related to MD virus but does not cause disease in chickens. 
Innovax-ILT je cepivo, ki vsebuje serotip 3 puranjega herpes virusa, tj. vrsto herpes virusa, ki je tesno povezan z virusom Marekove bolezni, vendar pri piščancih ne povzroča bolezni.
What are the risks associated with Innovax-ILT? 
Kakšna tveganja so povezana z zdravilom Innovax-ILT?
Since Innovax-ILT is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. 
Cepivo Innovax-ILT je živo cepivo, zato se sev cepiva izloča iz cepljenih ptic in se lahko razširi na purane.
Chickens were taken from the field trial and challenged (exposed to infection) in the laboratory to demonstrate protection after vaccination. 
Piščance iz terenskega preskušanja so nato prenesli v laboratorij, kjer so izvedli provokacijski test (jih izpostavili okužbi), da bi dokazali, da se je po cepljenju razvila zaščita.
Innovax-ILT contains live turkey herpesvirus strain HVT/ILT-138. 
Zdravilo Innovax-ILT vsebuje sev živega puranjega herpes virusa HVT/ILT-138.
Why is Innovax-ILT approved? 
Zakaj je bilo zdravilo Innovax-ILT odobreno?
Protection against ILT starts 4 weeks after vaccination and lasts 60 weeks. 
Zaščita pred infekcijskim laringotraheitisom se razvije štiri tedne po cepljenju in traja 60 tednov.
To evaluate the effects of the vaccine against MD, chickens vaccinated either with Innovax-ILT alone or Innovax-ILT mixed with Nobilis Rismavac (a vaccine which also protects against Marek's disease) were infected with very virulent strains of the MD virus. 
Da bi ovrednotili učinke cepiva proti Marekovi bolezni, so piščance, cepljene bodisi zgolj s cepivom Innovax-ILT bodisi s cepivom Innovax-ILT v kombinaciji s cepivom Nobilis Rismavac (cepivom, ki prav tako ščiti pred Marekovo boleznijo), okužili z zelo virulentnimi sevi virusa Marekove bolezni.
The level of protection in general was higher when Innovax-ILT was given alone. 
Stopnja zaščite je bila na splošno višja po cepljenju zgolj s cepivom Innovax-ILT.
MD is another herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. 
Marekova bolezen je prav tako okužba s herpes virusom, ki prizadene piščance in lahko povzroči paralizo kril in nog ter nastanek tumorjev v različnih organih.
For more information about treatment with Innovax-ILT, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom Innovax-ILT naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Safety information has been included in the summary of product characteristics and the package leaflet for Innovax-ILT, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
For practical information about using Innovax-ILT, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila Innovax-ILT naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Innovax-ILT is a veterinary vaccine used to protect chickens against infectious laryngotracheitis (ILT) and Marek's disease (MD). 
Innovax-ILT je cepivo za uporabo v veterinarski medicini, ki se uporablja za zaščito piščancev pred infekcijskim laringotraheitisom (ILT) in Marekovo boleznijo (MB).
A field trial in chickens was performed to evaluate the effects of the vaccine against ILT and MD. Mortality was low, no disease related signs were observed and the condition of the chickens was good throughout the trial, indicating effectiveness of the vaccine. 
Umrljivost je bila majhna, opazili niso nobenih z boleznijo povezanih znakov in tudi stanje piščancev je bilo skozi celotno preskušanje dobro, kar kaže na to, da je cepivo učinkovito.
In a second challenge study the effectiveness of the vaccination with Innovax-ILT alone and InnovaxILT mixed with Nobilis Rismavac was also examined by evaluation of protection after infection under laboratory conditions with the ILT virus. 
V drugi provokacijski študiji so učinkovitost cepljenja zgolj s cepivom Innovax-ILT in s cepivom Innovax-ILT v kombinaciji s cepivom Nobilis Rismavac raziskali tudi tako, da so ovrednotili zaščito po okužbi z virusom ILT v laboratorijskih pogojih.
When Innovax-ILT was applied mixed with Nobilis Rismavac, the start of protection against ILT was delayed by up to 10 weeks after vaccination. 
Po dajanju cepiva Innovax-ILT v kombinaciji s cepivom Nobilis Rismavac se je zaščita pred ILT razvila kasneje, in sicer do 10 tednov po cepljenju.
How does Innovax-ILT work? 
Kako zdravilo Innovax-ILT deluje?
How is Innovax-ILT used? 
Kako se zdravilo Innovax-ILT uporablja?
When Innovax-ILT is given mixed with Nobilis Rismavac protection against MD starts at 5 days after vaccination. 
Pri uporabi cepiva Innovax-ILT v kombinaciji s cepivom Nobilis Rismavac se zaščita pred Marekovo boleznijo razvije peti dan po cepljenju.
This will help protect the chickens against ILT and MD. 
To pomaga zaščititi piščance pred infekcijskim laringotraheitisom in Marekovo boleznijo.
Chickens showed varying levels of protection after vaccination with either Innovax-ILT alone or Innovax-ILT mixed with Nobilis Rismavac. 
Po cepljenju bodisi zgolj s cepivom Innovax-ILT bodisi s cepivom Innovax-ILT v kombinaciji s cepivom Nobilis Rismavac so pri piščancih opazili različne stopnje zaščite.
Chickens showed significant protection after both vaccination with Innovax-ILT alone and Innovax-ILT mixed with Nobilis Rismavac. 
Tako po cepljenju zgolj s cepivom Innovax-ILT kot s cepivom Innovax-ILT v kombinaciji s cepivom Nobilis Rismavac so pri piščancih opazili znatno zaščito.
It is available as tablets (50, 100, 200, 300 and 400 mg). 
Na voljo je v obliki tablet (50, 100, 200, 300 in 400 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Trobalt on 28 March 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Trobalt, veljavno po vsej Evropski uniji, odobrila dne 28. marca 2011.
The full EPAR for Trobalt can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Trobalt je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In the other two studies, the main measure of effectiveness was the number of patients whose number of seizures was at least halved. 
V drugih dveh študijah je bilo glavno merilo učinkovitosti število bolnikov, pri katerih se je število napadov vsaj prepolovilo.
Other information about Trobalt 
Druge informacije o zdravilu Trobalt
What measures are being taken to ensure the safe use of Trobalt? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Trobalt?
This is a summary of the European public assessment report (EPAR) for Trobalt. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Trobalt.
In the first study, the main measure of effectiveness was the change in the number of seizures per month. 
V prvi študiji je bilo glavno merilo učinkovitosti sprememba števila napadov na mesec.
What benefit has Trobalt shown during the studies? 
Kakšne koristi je zdravilo Trobalt izkazalo med študijami?
This will stop further transmission of electrical impulses thereby preventing epileptic seizures. 
To preprečuje nadaljnji prenos električnih signalov ter posledično epileptične napade.
The CHMP decided that the benefits of Trobalt are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Trobalt večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Epilepsy is caused by excessive electrical activity in the nerve cells of the brain. 
Epilepsijo povzroča prekomerna električna aktivnost v živčnih celicah v možganih.
The recommended maintenance dose is between 600 mg a day and a maximum of 1,200 mg a day. 
Priporočeni vzdrževalni odmerek znaša od 600 mg na dan do največ 1 200 mg na dan.
Treatment with Trobalt starts with one 100 mg tablet three times a day for one week; the dose is then increased weekly by 50 mg per dose according to the patient's response. 
Zdravljenje z zdravilom Trobalt se začne z enotedenskim zdravljenjem z eno 100-miligramsko tableto trikrat na dan, nato pa se ta odmerek vsak teden poveča za 50 mg v skladu z bolnikovim odzivom.
For more information on how to use Trobalt, including detailed recommendations for different patients groups, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o uporabi zdravila Trobalt, vključno s podrobnimi priporočili za posamezne skupine bolnikov, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
However, because of the risk of retinal discolouration, which could possibly result in impaired vision, the CHMP concluded that the use of Trobalt should be restricted only to those patients for whom other anti-epileptic medicines have proved inadequate or have not been tolerated. 
Vendar je zaradi tveganja za spremembo barve mrežnice, zaradi česar bi lahko prišlo do okvare vida, zaključil, da je treba uporabo zdravila Trobalt omejiti le na tiste bolnike, pri katerih so se druga zdravila proti epilepsiji izkazala za nezadostna ali jih ne prenašajo.
It is used in epilepsy with or without ‘secondary generalisation' (when the excessive electrical activity reaches the whole brain). 
Uporablja se pri epilepsiji s sekundarno generalizacijo (ko prekomerna električna aktivnost zajame celotne možgane) ali brez nje.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Trobalt. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Trobalt, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The effect of Trobalt at 600 mg a day was inconclusive in this study. 
Učinka jemanja 600 mg zdravila Trobalt na dan s to študijo ni bilo mogoče ovrednotiti.
These are pores that let potassium move in and out of the cell and play a role in terminating electrical impulses. 
Imajo obliko por, ki prepuščajo kalij v celico in iz nje ter imajo pomembno vlogo pri ustavljanju električnih signalov.
What is the risk associated with Trobalt? 
Kakšna tveganja so povezana z zdravilom Trobalt?
The company that makes Trobalt must ensure that doctors who are expected to prescribe Trobalt receive an information pack containing important safety information, including information on the risk of pigment changes in the eye and discolouration of the nails, lips and skin, and on the need for a full eye examination at the start of treatment and at least every 6 months during treatment. 
Družba, ki izdeluje zdravilo Trobalt, mora zdravnikom, ki bodo predpisovali zdravilo Trobalt, zagotoviti informativno gradivo, ki bo vsebovalo pomembne informacije o varnosti zdravila, vključno z informacijami o tveganju za pigmentne spremembe v očeh ter spremembo barve nohtov, ustnic in kože ter o nujnosti za temeljit pregled oči na začetku zdravljenja in vsaj vsakih šest mesecev med zdravljenjem.
For more information about treatment with Trobalt, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Trobalt preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is a type of epilepsy where too much electrical activity in one part of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness or a sudden sense of fear. 
To je vrsta epilepsije, pri kateri prevelika električna aktivnost v enem delu možganov povzroči simptome, kot so nenadni sunkoviti gibi enega dela telesa, motnje sluha, voha ali vida, odrevenelost ali nenaden občutek strahu.
Trobalt was more effective than placebo in reducing the number of seizures. 
Zdravilo Trobalt je bilo pri zmanjševanju števila napadov učinkovitejše od placeba.
Trobalt has been compared with placebo (a dummy treatment) in three main studies involving a total of 1,244 patients whose seizures were not adequately controlled with other anti-epileptic medicines. 
Zdravilo Trobalt so primerjali s placebom (zdravilom brez zdravilne učinkovine) v treh glavnih študijah, ki so vključevale skupno 1 244 bolnikov, pri katerih napadov ni bilo mogoče ustrezno nadzorovati z drugimi zdravili proti epilepsiji.
Lower doses should be used in older patients and in patients with moderate or severe liver or kidney problems. 
Starejši bolniki in bolniki z zmernim ali hudim obolenjem jeter ali ledvic morajo uporabljati manjše odmerke.
Trobalt is used in combination with other anti-epileptic medicines to treat adults with drug-resistant partial-onset seizures (epileptic fits) that cannot be treated with other combinations of medicines. 
Zdravilo Trobalt se uporablja v kombinaciji z drugimi zdravili proti epilepsiji za zdravljenje proti zdravilom odpornih konvulzij s parcialnim začetkom (epileptičnih napadov) pri odraslih, ki jih ni mogoče zdraviti z drugimi kombinacijami zdravil.
Trobalt must not be used in people who are hypersensitive (allergic) to retigabine or any of the other ingredients. 
Zdravila Trobalt ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) retigabin ali katero koli drugo sestavino zdravila.
Trobalt has an effect on the potassium channels located on the nerve cells of the brain. 
Zdravilo Trobalt vpliva na kalijeve kanale, ki se nahajajo na živčnih celicah v možganih.
Why has Trobalt been approved? 
Zakaj je bilo zdravilo Trobalt odobreno?
For the full list of all side effects reported with Trobalt, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Trobalt, glejte navodilo za uporabo.
Trobalt is a medicine that contains the active substance retigabine. 
Trobalt je zdravilo, ki vsebuje zdravilno učinkovino retigabin.
The most common side effects with Trobalt (seen in more than 1 patient in 10) are dizziness, somnolence (sleepiness), fatigue (tiredness) as well as pigment changes (discolouration) of parts of the eye (including the retina, the light sensitive membrane at the back of the eye) and discolouration of the nails, lips and skin, which have been reported after several years of treatment. 
Najpogostejši neželeni učinki zdravila Trobalt (opaženi pri več kot 1 bolniku izmed 10) so omotica, zaspanost, utrujenost ter pigmentne spremembe (sprememba barve) delov oči (vključno z mrežnico, na svetlobo občutljivo membrano v ozadju očesa) in sprememba barve nohtov, ustnic in kože, o čemer so poročali po večletnem zdravljenju.
It will also include information on some less common side effects that have been reported with the medicine, such as problems with passing urine, prolonged QT interval (an alteration of the electrical activity of the heart) and hallucinations (seeing or hearing things that are not there). 
Gradivo bo vsebovalo tudi informacije o nekaterih manj pogostih neželenih učinkih, o katerih so poročali pri uporabi zdravila, kot so na primer težave pri uriniranju, podaljšan interval QT (sprememba električne aktivnosti srca) ter halucinacije (prividi ali prisluhi).
Trobalt acts by keeping the potassium channels open. 
Zdravilo Trobalt deluje tako, da ohranja kalijeve kanale odprte.
The active substance in Trobalt, retigabine, is an anti-epileptic medicine. 
Zdravilna učinkovina zdravila Trobalt, retigabin, je zdravilo za zdravljenje epilepsije.
In the first study, Trobalt at 900 mg a day and 1,200 mg a day was more effective than placebo and reduced the number of seizures per month by 29% and 35% respectively. 
V prvi študiji je bilo jemanje 900 mg in 1 200 mg zdravila Trobalt na dan učinkovitejše od placeba in je število mesečnih napadov zmanjšalo za 29 % oziroma 35 %.
The CHMP noted that Trobalt is effective at reducing the number of seizures. 
Menil je, da je zdravilo Trobalt učinkovito pri zmanjševanju števila napadov.
Trobalt at a maintenance dose of 600, 900 or 1,200 mg a day or placebo was taken for 8 weeks in the first study and 12 weeks in the other two studies. 
V prvi študiji so bolniki prejemali 600-, 900- ali 1 200-miligramski vzdrževalni odmerek zdravila Trobalt na dan ali placebo osem tednov, v drugih dveh študijah pa 12 tednov.
In the second study, seizures were at least halved in 39% (61 out of 158 patients) of the patients on 600 mg Trobalt a day and in 47% (70 out of 149 patients) of the patients on 900 mg a day, compared with 19% (31 out of 164) of the patients on placebo. 
V drugi študiji se je število napadov najmanj prepolovilo pri 39 % (61 od 158) bolnikov, ki so prejemali 600 mg zdravila Trobalt na dan, in 47 % (70 od 149) bolnikov, ki so prejemali 900 mg zdravila na dan, medtem ko je v skupini, ki je prejemala placebo, do tega prišlo pri 19 % (31 od 164) bolnikov.
This compared with a reduction of 13% in the placebo group. 
V primerjavi s tem se je v skupini, ki je prejemala placebo, število mesečnih napadov zmanjšalo za 13 %.
In the third study, seizures were at least halved in 56% (66 out of 119 patients) of the patients taking 1,200 mg Trobalt a day, compared with 23% (31 out of 137) of the patients on placebo. 
V tretji študiji se je število napadov najmanj prepolovilo pri 56 % (66 od 119) bolnikov, ki so jemali 1 200 mg zdravila Trobalt na dan, v skupini bolnikov, ki so prejemali placebo, pa pri 23 % (31 od 137) bolnikov.
What is Trobalt used for? 
Za kaj se zdravilo Trobalt uporablja?
How has Trobalt been studied? 
Kako je bilo zdravilo Trobalt raziskano?
What is Trobalt? 
Kaj je zdravilo Trobalt?
How is Trobalt used? 
Kako se zdravilo Trobalt uporablja?
How does Trobalt work? 
Kako zdravilo Trobalt deluje?
The maximum dose is 25.2 g once a day. 
Največji odmerek je 25,2 g enkrat na dan.
The recommended starting dose is 8.4 g once a day. 
Priporočeni začetni odmerek je 8,4 g enkrat na dan.
What measures are being taken to ensure the safe and effective use of Veltassa? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Veltassa?
The full EPAR for Veltassa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Veltassa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Hyperkalaemia can cause serious heart problems and muscle weakness. 
Hiperkaliemija lahko povzroči hude težave s srcem in oslabelost mišic.
Other information about Veltassa 
Druge informacije o zdravilu Veltassa
This is a summary of the European public assessment report (EPAR) for Veltassa. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Veltassa.
The European Medicines Agency decided that Veltassa's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Veltassa večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
The side effects are relatively moderate but the doctor should take them into account when considering treatment with Veltassa. 
Neželeni učinki so sorazmerno zmerni, vendar jih mora zdravnik ob načrtovanju zdravljenja z zdravilom Veltassa upoštevati.
The Veltassa mixture should be taken with food and at least 3 hours before or after any other medicines the patient takes by mouth. 
Mešanico zdravila Veltassa je treba vzeti s hrano in vsaj tri ure pred jemanjem drugih peroralnih zdravil ali po tem.
Veltassa is available as sachets (8.4, 16.8 and 25.2 g) of patiromer containing a powder for mixing with water or some fruit juices and taking by mouth. 
Zdravilo Veltassa je na voljo v obliki vrečic (8,4 g, 16,8 g in 25,2 g) patiromera, ki vsebujejo prašek, ki se zmeša z vodo ali nekaterimi sadnimi sokovi, in se zaužije peroralno.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Veltassa have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Veltassa upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
What are the risks associated with Veltassa? 
Kakšna tveganja so povezana z zdravilom Veltassa?
What benefits of Veltassa have been shown in studies? 
Kakšne koristi je zdravilo Veltassa izkazalo v študijah?
After 4 weeks of treatment, their potassium level fell on average by 1.0 mmol/litre. 
Po štirih tednih zdravljenja se je njihova raven kalija povprečno znižala za 1,0 mmol/liter.
The most common side effects with Veltassa (which may affect more than 1 in 100 people) are those affecting the digestive system (constipation, diarrhoea, abdominal pain and wind) and blood tests showing low levels of magnesium in the blood. 
Najpogostejši neželeni učinki zdravila Veltassa (ki se lahko pojavijo pri več kot 1 bolniku od 100) so učinki na prebavila (zaprtost, driska, bolečine v trebuhu in vetrovi) in rezultati krvnih preiskav, ki kažejo na nizko raven magnezija v krvi.
For more information about treatment with Veltassa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Veltassa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Veltassa and what is it used for? 
Kaj je zdravilo Veltassa in za kaj se uporablja?
patiromer draws potassium from the body into the gut and so reduces the amount of potassium in the blood. 
Na ta način patiromer izloči kalij iz telesa v črevo ter zmanjša količino kalija v krvi.
Why is Veltassa approved? 
Zakaj je bilo zdravilo Veltassa odobreno?
It is not intended to provide practical advice on how to use Veltassa. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.